Can a radioactive 'Smart Bomb' take down resistant childhood cancers?

NCT ID NCT03015844

AVAILABLE Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study offers access to a radioactive therapy called 131I-MIBG for people with neuroblastoma or pheochromocytoma that has returned or stopped responding to standard treatments. The therapy is designed to seek out and deliver radiation directly to tumor cells. Researchers are evaluating how well it controls symptoms, its side effects, and how long it may slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 131I-MIBG (iobenguane), a radioactive molecule that targets and delivers radiation to tumor cells
What this could lead to: If effective, this therapy could offer a way to shrink tumors and ease symptoms for people with these rare cancers who have run out of standard options.
What could go wrong: This is an early-access, compassionate-use program, not a large controlled trial, so benefits are uncertain. The treatment carries risks of toxicity, including damage to bone marrow and other organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma pheochromocytoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA PHEOCHROMOCYTOMA

Contacts and locations

Locations

Cohen Children's Medical Center
AVAILABLE

New Hyde Park, New York, 11040, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.